Search Medical Condition
Please enter condition
Please choose location from dropdown

Jakarta Barat, Indonesia Clinical Trials

A listing of Jakarta Barat, Indonesia clinical trials actively recruiting patients volunteers.

RESULTS

Found (12) clinical trials

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Aspirin in patients with dukes C or high risk dukes B colorectal cancer can improve survival in this patient population over placebo control. Eligible patients will be randomized to treatment arms, using the following stratification factors Study Centre Tumour Type Type of adjuvant chemotherapy received(exposed/not exposed to oxaliplatin Patients will ...

Phase

3.37 miles

Learn More »

The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension in National Cardiovascular Center Harapan Kita Hospital

Right ventricular dysfunction is the worst mortality predictor in pulmonary arterial hypertension (PAH). Recent study has described that approximately 25% of PAH patients will developed into right ventricular failure despite therapeutic reduction of pulmonary vascular resistance. Subsequently, several studies have shown that fatty acid accumulation in right ventricle was inversely ...

Phase

3.37 miles

Learn More »

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT) between 2011 and 2016. The primary end points are overall survival (OS) and progression free survival (PFS) with Kaplan Meier. This study was ...

Phase

3.37 miles

Learn More »

Jakarta Acute Coronary Syndrome Registry

The JAC registry is an ongoing prospective, multi center, observational study that aims to enroll ACS patients who admitted to the emergency department (ED) of all health centers in Jakarta and the surrounding area. The registry has been collecting data since 2007, and used extensively since 2014. Currently, the JAC ...

Phase N/A

3.37 miles

Learn More »

DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis

There will be three groups of treatment by dosage regimen in this study. Eligible subjects will be randomized to receive any of the following regimens: 1) DLBS1442 at a dose of 3 x 100 mg daily, or 2) DLBS1442 at a dose of 3 x 200 mg daily; or 3) ...

Phase

5.32 miles

Learn More »

NeuroAiD Safe Treatment Registry

The NeST Registry is designed as a product registry that would provide information on the use and safety of NeuroAiD in clinical practice. An online NeST Registry was set up to allow easy entry and retrieval of essential information including demographics, medical conditions, clinical assessments of neurological, functional, and cognitive ...

Phase N/A

7.31 miles

Learn More »

Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

The aim of the study is to improve the loco-regional control rate and overall survival of locally advanced head and neck squamous carcinoma (HNSCC). We hypothesize that the addition of nimotuzumab (a recombinant humanized murine immune antibody that blocks both epidermal growth factor (EGF) and transforming growth factor (TGF)) to ...

Phase

7.31 miles

Learn More »

DLBS1033 for Acute Ischemic Stroke Patients

Subjects in this study will be screened consecutively and eligible subjects will be randomized into two groups and receive the investigational drug, DLBS1033 at a dose of 490 mg three times daily or its placebo in addition to standard therapy for 28-days course of therapy. Standard therapy used in this ...

Phase

7.31 miles

Learn More »

Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis

Results from clinical trials in Papua New Guinea and Cote d'Ivoire have shown that a single dose of three drugs (ivermectin, diethylcarbamazine, and albendazole [IDA]) was superior to standard two drug therapy (diethylcarbamazine and albendazole [DA]) in clearing W. bancrofti microfilaremia (MF) (King et al. unpublished data).1 Recently, large safety ...

Phase N/A

7.31 miles

Learn More »